Intellia Therapeutics Inc (NASDAQ:NTLA) shares, rose in value on Wednesday, July 09, with the stock price up by 9.08% to the previous day’s close as strong demand from buyers drove the stock to $12.13.
Actively observing the price movement in the last trading, the stock closed the session at $11.12, falling within a range of $11.4001 and $12.245. The value of beta (5-year monthly) was 2.134. Referring to stock’s 52-week performance, its high was $28.18, and the low was $5.90. On the whole, NTLA has fluctuated by 49.94% over the past month.
With the market capitalization of Intellia Therapeutics Inc currently standing at about $1.26 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-08.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 12.26M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NTLA’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of NTLA currently trading nearly 25.96% and 37.01% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 74.26, while the 7-day volatility ratio is showing 8.22% which for the 30-day chart, stands at 7.63%. Furthermore, Intellia Therapeutics Inc (NTLA)’s beta value is 2.29.
A comparison of Intellia Therapeutics Inc (NTLA) with its peers suggests the former has fared considerably weaker in the market. NTLA showed an intraday change of 9.08% in last session, and over the past year, it grew by 4.03%%.
Data on historical trading for Intellia Therapeutics Inc (NASDAQ:NTLA) indicates that the trading volumes over the past 10 days have averaged 4.57 and over the past 3 months, they’ve averaged 4.49 million. According to company’s latest data on outstanding shares, there are 103.54 million shares outstanding.
Nearly 5.95% of Intellia Therapeutics Inc’s shares belong to company insiders and institutional investors own 92.31% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 29.69 million shares as on 2025-06-13, resulting in a short ratio of 5.61. According to the data, the short interest in Intellia Therapeutics Inc (NTLA) stood at 3263.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 30.7 million. The stock has fallen by -46.70% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NTLA stock heading into the next quarter.
